Firategrast is primarily investigated for its potential therapeutic applications in the treatment of multiple sclerosis (MS). It functions as an α4β1 integrin antagonist, which helps in reducing the migration of immune cells across the blood-brain barrier. By inhibiting this migration, Firategrast aims to decrease the inflammatory processes that contribute to the damage of nerve cells in MS patients. This mechanism is crucial in managing the progression of the disease and alleviating symptoms. Clinical trials have explored its efficacy and safety, focusing on its ability to reduce relapse rates and improve overall neurological function in individuals with relapsing-remitting MS.